Acrofacial vitiligo secondary to PI3KCA inhibitor, alpelisib: case report.
| Autor: | Hinich MG; Oncology Division, Ziv Medical Centre, Safed, Israel., Hijab A; Oncology Division, Ziv Medical Centre, Safed, Israel.; Radiotherapy Unit, Ziv Medical Centre, Safed, Israel. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Frontiers in oncology [Front Oncol] 2023 Oct 30; Vol. 13, pp. 1255832. Date of Electronic Publication: 2023 Oct 30 (Print Publication: 2023). |
| DOI: | 10.3389/fonc.2023.1255832 |
| Abstrakt: | Alpelisib plus fulvestrant is a valid second or advanced line of treatment for patients with metastatic hormone receptor (HR)-positive, HER2-negative breast cancer who harbor an activating PIK3CA mutation. The well-known side effects of alpelisib are hyperglycemia, rash, and diarrhea. Herein, we report a case of a woman who developed diffuse depigmented macules on the face, arms and legs, three months after initiating alpelisib. Both clinical and histopathological findings were consistent with new-onset vitiligo. To our knowledge, this is the first case described in literature which suggests a causal relationship between alpelisib and irreversible dermatological adverse effect. Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. (Copyright © 2023 Hinich and Hijab.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|